Regulatory
FDA Has Proposed Keeping Semaglutide and Tirzepatide Off the 503B Bulks List
The FDA proposed keeping semaglutide and tirzepatide off the 503B Bulks List. What that means for compounded GLP-1s, and what happens next.
Regulatory · Analysis
FDA Has Proposed Keeping Semaglutide and Tirzepatide Off the 503B Bulks List
The FDA proposed keeping semaglutide and tirzepatide off the 503B Bulks List. What that means for compounded GLP-1s, and what happens next.
By peptidesmedia Editorial Desk ·
Safety
No published article yet. The beat starts when a named author is assigned.
GLP-1
No published article yet. The beat starts when a named author is assigned.
Legality
No published article yet. The beat starts when a named author is assigned.
The beat
Latest from the regulatory beat
Dated, re-reviewed coverage of peptide regulation, safety and evidence.
Reference
Peptides A–Z
Each entry covers what it is, the evidence grade, safety, and current legal status — dated and medically reviewed.
- BPC-157
Synthetic peptide
Unapproved drug - Semaglutide
GLP-1 agonist
FDA-approved - Tirzepatide
GIP/GLP-1 agonist
FDA-approved - TB-500
Thymosin β4 fragment
Unapproved drug - Collagen Peptides
Hydrolysed collagen
Dietary supplement
Start here
Three ways in
New to peptides, or just want the current state of play? Start with one of these.
Which Peptides Are FDA-Approved? The Status Tracker
A maintained, dated tracker of the FDA status of every peptide we cover — and what each status actually permits.
Open the tracker →Do Peptides Actually Work? What the Research Shows
What the published evidence supports, what it does not, and how to tell the difference between an anecdote and a trial.
Read on →GLP-1 Medications: The Hub
The approved GLP-1 medicines, how they differ, what they cost, and where compounded versions fit.
Read on →
The brief
Get the regulatory brief, every Friday
What changed in peptide regulation, safety and evidence this week. Independent and seller-free.
We sell nothing. Unsubscribe anytime.